Roche: Q1 sales up 3% at CHF14.9bn

(CercleFinance.com) - Roche's Q1 consolidated sales rose by 3% (-1% in Swiss francs) to 14.
9 billion Swiss francs.

Pharma division sales fell by 9% to 10.6 billion Swiss francs, mainly due to continued competition from biosimilars and the COVID-19 pandemic, it said.

In the US, sales declined by 14%, reflecting continued competition from biosimilars for drugs. In Europe, sales were down 6% as "demand for the new products (including the antibody combination casirivimab/imdevimab) was only partly able to offset the impact of lower sales for the established cancer medicines (mainly Avastin) and impacts of the COVID-19 pandemic," the group added.

Sales are expected to increase in the low to mid-single digits at constant exchange rates. Core EPS is expected to grow broadly in line with sales at constant exchange rates. Roche expects to further increase its dividend in Swiss francs.


Copyright (c) 2021 CercleFinance.com. All rights reserved.